PERRIGO PHARMA INTL
SpecialtyPERRIGO PHARMA INTL is a specialty pharmaceutical company focused on Immunology, Cardiovascular. Key products include NASONEX 24HR ALLERGY.
PERRIGO PHARMA INTL's Key Drugs
PERRIGO PHARMA INTL's core commercial portfolio centers on NASONEX 24HR ALLERGY, spanning Immunology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
PERRIGO PHARMA INTL's Recent FDA Approvals
New NDA/BLA approvals for PERRIGO PHARMA INTL over the last two years — novel drugs only, excluding generics and label supplements.
PERRIGO PHARMA INTL's Therapeutic Areas
PERRIGO PHARMA INTL's approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Cardiovascular, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PERRIGO PHARMA INTL's Top Competitors
PERRIGO PHARMA INTL's closest competitors by therapeutic-area and drug-target overlap include Novartis, Sanofi, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PERRIGO PHARMA INTL Pipeline Snapshot
Active clinical trials for PERRIGO PHARMA INTL across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • NASONEX 24HR ALLERGY leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2003-01-30
- Latest
- 2024-06-07
- Applications
- 10